Close Window

Financial Tear Sheet

CORPORATE PROFILE

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis' development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drug to the right patient at the right time – represents the future of cancer therapy.

We have one marketed product, Rubraca™ (rucaparib). For information on our marketed product, click here.

Our lead product candidate under active development is rucaparib, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1, 2 and 3. Rucaparib is in advanced clinical development for the treatment of ovarian cancer and we are initiating clinical developmentfor the treatment of metastatic castration-resistant prostate cancer patients. We maintain global rights to rucaparib.

In addition, we have two other product candidates: rociletinib; an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR), for which we have terminated enrollment in all ongoing sponsored clinical studies, though we continue to provide drug to patients whose clinicians recommend continuing rociletinib therapy. We are continuing analyses of rociletinib data to determine whether certain populations of patients may represent an opportunity for a partner committed to investing in further clinical development. Lucitanib; an oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR a/ß) and fibroblast growth factor receptors 1 through 3 (FGFR1-3). Lucitanib was previously evaluated in breast and lung cancers. Development in those indications has ceased and we continue to provide drug to patients whose clinicians recommend continuing lucitanib therapy. Along with our development partner, Les Laboratoires Servier (Servier), we are continuing to evaluate development options for lucitanib.

We maintain global rights to rociletinib and exclusive development and commercial rights to lucitanib on a global basis, excluding China. Lucitanib rights to markets outside of the U.S. and Japan have been sublicensed to Servier.

PRIMARY IR CONTACTS

Breanna Burkart
Phone: 303.625.5023
E-mail:
bburkart@clovisoncology.com

Anna Sussman
Phone: 303.625.5022
E-mail:
asussman@clovisoncology.com

STOCK PERFORMANCE

CLVS (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Price	$52.17
Change (%)	▼ 2.87 (5.21%)
Volume	1,108,558
52 Week Low	$11.57
Market Cap	$2,335,786,542
Rolling EPS	-8.23
PE Ratio	N/A
Shares Outstanding	44,772,600

Data as of 05/26/17 4:00 p.m. ET



RECENT HEADLINES & EVENTS

05/23/17
Clovis Oncology Announces Presentations at 2017 ASCO Annual Meeting

05/03/17
Clovis Oncology Announces First Quarter 2017 Operating Results

04/27/17
Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment

Date	Title
06/02/17 through 06/06/17	Clovis Oncology, Inc. at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting Location Chicago, IL

SEC FILINGS

Filing Date	Form
05/23/17	4/A
05/15/17	4
05/04/17	10-Q
05/03/17	8-K